...
首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >DNA-BASED HYBRID LIQUID CRYSTALLINE NANO ORGANOMETALLIC COMPOSITES FOR TARGETED DRUG DELIVERY IN NEUTRON CAPTURE THERAPY
【24h】

DNA-BASED HYBRID LIQUID CRYSTALLINE NANO ORGANOMETALLIC COMPOSITES FOR TARGETED DRUG DELIVERY IN NEUTRON CAPTURE THERAPY

机译:用于中子捕获治疗中靶向药物的基于DNA的混合液态纳米纳米有机复合材料

获取原文
           

摘要

Objective: The aim of this work was focused on the obtaining a DNA-based hybrid nano liquid crystalline organometallic composites for targeted drug delivery in neutron capture therapy. Methods: The formation of a cholesteric liquid crystalline DNA (CLCD-DNA) dispersion has performed using ultrasonic depolymerized calf thymus DNA(MW-0.6-0.8×10 6 Da)2×10 -7 M, mixing with polyethylene glycol8.5×10 -5 M, dissolved in the 0.3 M NaCl solution and incubated over 1,0 h at 20 °C. CLCD-DNA formation process was determined and controlled by measuring absorption value of circular dichroism (CD) spectrum in the range of 350-600 nm. The organometallic DNA-Gd compound was formed by processing the obtained CLCD-DNA with 2.49 × 10 -4 M, 4.97 × 10 -4 M, 9.8 × 10 -4 M, 1.48× 10 -3 M, 2.92 × 10 -3 M GdCl 3 aqueous solutions. CLCD-DNA-gadolinium complex formation process was registered over the appearance of 2 nd amplitude in the CD spectrum. DNA-Gd complex dispersion toxicity was evaluated over 40 min, 24h and 72h incubation with 1×10 6 cells in the RPMI-40 medium supplemented with 3×10 -4 M Gd 3+ . Results: The obtained CLCD-DNA-Gd (d~500 nm) particles was shown less toxicity and higher viability percentage of macrophages after 40 min incubation with CLCD-DNA-Gd contains Gd 3+ ions concentration 3×10 -4 M showed 100% viability and after 72 h ours approximately 89%. The cells immobilized with CLCD-DNA-Gd particles contains 3×10 -4 M Gd 3+ , neutron irritation was caused a 100% cell deaths. Conclusion: Obtained relatively stable, non-cytotoxic drug forms with a maximum local concentration of gadolinium (400 μg/ml). The effectiveness of these nanosystems for targeted drug delivery has markedly superior efficacy than 10 B and other products were based on gadolinium.
机译:目的:这项工作的目的集中在获得一种基于DNA的杂化纳米液晶有机金属复合材料,用于中子俘获治疗中的靶向药物输送。方法:采用超声解聚的小牛胸腺DNA(MW-0.6-0.8×10 6 Da)2×10 -7 M,与聚乙二醇8.5×10混合,形成胆甾型液晶DNA(CLCD-DNA)分散体。 -5 M,溶于0.3 M NaCl溶液中,在20°C下温育1,0 h。通过测量圆二色性(CD)光谱在350-600 nm范围内的吸收值来确定和控制CLCD-DNA的形成过程。通过用2.49×10 -4 M,4.97×10 -4 M,9.8×10 -4 M,1.48×10 -3 M,2.92×10 -3 M处理获得的CLCD-DNA来形成有机金属DNA-Gd化合物。 GdCl 3水溶液。 CLCD-DNA-ga络合物的形成过程在CD光谱中出现了第二个振幅时出现。在补充了3×10 -4 M Gd 3+的RPMI-40培养基中,用1×10 6个细胞孵育40分钟,24小时和72小时,评估了DNA-Gd复合物的分散毒性。结果:所获得的CLCD-DNA-Gd(d〜500 nm)颗粒经CLCD-DNA-Gd孵育40分钟后,其含有的Gd 3+离子浓度为3×10 -4 M,显示毒性较小,巨噬细胞的存活率较高,显示为100 %的存活率,72小时后约为89%。固定有CLCD-DNA-Gd颗粒的细胞含有3×10 -4 M Gd 3+,中子刺激引起100%细胞死亡。结论:获得了相对稳定的,无细胞毒性的药物形式,最大局部concentration浓度为(400μg/ ml)。这些纳米系统用于靶向药物输送的功效比10 B明显优越,其他产品均基于g。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号